Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest MedImmune Stories

2011-04-29 01:29:45

A study of H1N1 and seasonal influenza vaccination in a sample of black and Hispanic children in Atlanta found a low rate of vaccine acceptance among parents and caregivers. Only 36 percent of parents and caregivers indicated they would immunize children against H1N1, and 22 percent indicated their children received the seasonal influenza vaccine in the previous three months. The majority of children in the sample (71 percent) were from households with less than $40,000 in annual income....

2011-04-26 06:00:00

SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu. The diagnostic test, which runs on Cepheid's GeneXpert® System, simultaneously detects and differentiates Influenza A, Influenza B, and the 2009 H1N1 influenza virus in about one hour. (Photo: http://photos.prnewswire.com/prnh/20110426/LA89263) "With Xpert Flu,...

2011-04-19 15:10:00

ROCKVILLE, Md., April 19, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Stanley C. Erck, its former Executive Chairman, has been appointed to the position of President and Chief Executive Officer and will remain as a member of the Board of Directors. In addition, current Board member James Young, Ph.D., will assume the position of Chairman of the Board. Mr. Erck has been an active member of Novavax's senior management team for the last year and has had extensive...

2011-03-30 16:00:00

QUEBEC CITY, QC, March 30 /PRNewswire-FirstCall/ -  Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced its operational and financial results for the fourth quarter and year ended December 31, 2010. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. Highlights...

2011-03-29 09:25:00

WASHINGTON, March 29, 2011 /PRNewswire/ -- MedImmune announced today it will present a total of 11 abstracts at the 45th National Immunization Conference (NIC) at the Washington Hilton in Washington, DC, March 28 - 31, 2011. These abstracts advance the body of existing data and knowledge surrounding influenza prevention and trends in vaccination, highlighting MedImmune's strong leadership in patient health in various medical settings. "MedImmune is pleased to announce new research on...

2011-03-21 06:00:00

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, March 21 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the first dose of vaccine has been administered thereby initiating the Company's phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine")...

2011-03-03 11:49:00

ROCKVILLE, Md., March 3, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Maryland State Governor Martin O'Malley will visit the company's headquarters in Rockville, Maryland, on Monday, March 7, to celebrate the recently announced contract valued at up to $179 million. The Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human...

2011-03-01 07:30:00

ROCKVILLE, Md., March 1, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has been awarded a contract valued at up to $179 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS) for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic...

2011-03-01 01:35:00

VIENNA, March 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs. Increase in IXIARO®/JESPECT® sales by approximately 66% to EUR 12.8m for the full year 2010, due to increased sales in key travel markets and to U.S. military. EUR 255.2m net loss for the full year 2010 resulting mainly from...

2011-02-28 15:00:00

INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2010. Total revenues in 2010 were $345.0 million, compared to $318.2 million in 2009. Excluding 2009 royalty revenues for sales of Synagis® received from MedImmune, royalty revenues for 2010 increased 30 percent over 2009. For the fourth quarter of 2010, total revenues were $76.1 million,...